Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by BlueMetal75on Nov 29, 2019 6:49pm
147 Views
Post# 30407489

RE:RE:RE:Well I guess we can forget about...

RE:RE:RE:Well I guess we can forget about...Macer, you're out of your mind.

The IND was submitted at beginning of Oct. By rule, FDA must respond with questions within 30 days, or it's automatically approved. This means that the FDA had already asked for more clarification by the end of Oct. The company didn't bother to inform us of this fact. So the company responded to the FDA's questions, and this response was so concerning that on Nov 25 the FDA issued a Full Clinical Stop! Wow!

Think about that. And then tell me again this isn't a disaster. Esp when you realize that this roughly six month delay (and that's assuming we get this all cleared up and approved by April) will cost the company over a million dollars at the current burn rate (as revealed in today's PR). But there's nothing to see here and all is well? Are you nuts?

Again, I want to know who was responsible for this debacle, and what consequences they will face. I will call the company next week to let them know exactly what I think, and to demand some accountability.
Bullboard Posts